On Wednesday, First Bancorp (NYSE:FBP)’s shares declined -1.27% to $3.88.
First BanCorp (FBP), the bank holding company for FirstBank Puerto Rico, is happy to declare the results of its 2015 company-run capital stress test (“Dodd-Frank Act Stress Test” or “DFAST”). First BanCorp is required to disclose the results of the DFAST annually, starting with the 2015 test.
Results indicate that, even in the severely adverse scenario presented by the test, First BanCorp’s capital ratios exceed both the regulatory minimum required ratios mandated under Basel III and the well-capitalized thresholds throughout the nine-quarter time horizon.
First BanCorp. operates as the bank holding company for FirstBank Puerto Rico that provides a range of financial products and services to retail, commercial, and institutional clients. Its Commercial and Corporate Banking segment offers commercial real estate and construction loans, and floor plan financings; and cash administration and business administration services, in addition to underwrites bonds and financial advisory services offered to government entities.
Garmin Ltd. (NASDAQ:GRMN)’s shares gained 0.25% to $40.34.
The Garmin Ltd.(GRMN) board of directors has established September 30, 2015 as the payment date for the next dividend installment of $0.51 per share with a record date of September 15, 2015, per the approval formerly offered at the 2015 annual shareholders’ meeting. At the 2015 annual meeting Garmin shareholders, in accordance with Swiss corporate law, approved a cash dividend in the total amount of $2.04 per share (subject to possible adjustment based on the total amount of the dividend in Swiss Francs), payable in four equal installments on dates to be determined by the board in its discretion.
Garmin Ltd., together with its auxiliaries, designs, develops, manufactures, and markets hand-held, wrist-based, and portable and fixed-mount global positioning system (GPS) enabled products; and other navigation, communication, and information products worldwide. It operates in five segments: Automotive/Mobile, Aviation, Marine, Outdoor, and Fitness.
At the end of Wednesday’s trade, Curis, Inc. (NASDAQ:CRIS)‘s shares surged 0.38% to $2.61.
Curis, Inc. (CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, stated its financial results for the second quarter ended June 30, 2015.
Second Quarter and First Half 2015 Financial Results
Curis stated a net loss of $8.1 million, or ($0.06) per share on both a basic and fully diluted basis for the second quarter of 2015, as contrast to a net loss of $1.9 million or ($0.02) per share on both a basic and fully diluted basis for the same period in 2014. Curis stated a net loss of $40 million, or ($0.34) per share on both a basic and fully diluted basis for the six months ended June 30, 2015, as contrast to a net loss of $7.5 million or ($0.09) per share on both a basic and fully diluted basis for the same period in 2014. The net loss for the first half of 2015 comprises an in-process research and development charge of $24.3 million related to Curis’ license agreement with Aurigene.
Revenues for the second quarter of 2015 were $2.1 million, as contrast to $4.8 million for the same period in 2014. The decrease in revenues was primarily due to a decrease in license fee revenues due to a $3 million milestone payment that Curis earned from Genentech/Roche upon achievement by Genentech/Roche of certain development objectives during the second quarter of 2014. Offsetting these decreases, royalty revenues recorded on Genentech/Roche’s net sales of Erivedge rose to $2.0 million in the second quarter of 2015 as contrast to $1.8 million during the same period in 2014.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase I clinical trials for advanced lymphomas and multiple myeloma; and HER 2-/ ER+ or PR+ breast cancer, and NUT midline carcinoma.
Unwired Planet Inc (NASDAQ:UPIP), ended its Wednesday’s trading session with 6.39% gain, and closed at $0.745.
Unwired Planet, Inc. (UPIP) declared that its annual meeting of shareholders is planned to take place on December 4, 2015. Shareholders of record as of the close of business on October 6, 2015, the record date for the meeting, will be entitled to vote at the meeting.
Unwired Planet, Inc., an intellectual property licensing company, develops patents that allow mobile devices to connect to the Internet worldwide. As of August 14, 2014, the company’s patent portfolio comprised of about 2,500 issued and pending U.S. and foreign patents. Its patents cover various 2G, 3G, and 4G technologies, in addition to cloud-based mobile applications and services.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
